Quantoom Biosciences is growing in Evry Quantoom Biosciences, a Belgian biotech dedicated to mRNA production and part of the global life science group Univercells, is opening a brand-new facility in Évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but…..
EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles EUROAPI, the European CDMO announced by Sanofi in February 2020, has expanded its collaboration with the French group under the umbrella of their Master Agreement for Development and GMP Manufacturing Services, dated October 1, 2021, to support…..
CordenPharma Chenôve increases lipid manufacturing capacity to support mRNA vaccine strategy CordenPharma, a full-service CDMO, has kicked off a major investment project to increase lipid manufacturing capacity at its Chenôve facility, near Dijon, France. This strategic decision was a result of the greatly increased demand to supply millions of…..
Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics
Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics Touchlight, a UK biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has concluded a development and manufacturing pipeline agreement with Versameb, a Swiss pre-clinical stage company focused on discovering and…..
A new agent for brain diseases: mRNA Brain-derived neurotrophic factor mRNA therapeutics for ischemic neuronal death using polyplex nanomicelle. Department of Biofunction Research,TMDU© Brain-derived neurotrophic factor (BDNF) enhances the survival and function of neurons and could serve as a potential candidate neuroprotective agent. However, this protein is too large to…..
Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases ConserV Bioscience, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA, a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its TriMix technology,…..
More than 580 gene therapy products are under development in biotech and pharmaceutical companies for the treatment of more than 240 diseases. More than 200 of these products are now at the clinical stage. After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019) In…..
Gene Therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. BioPharmAnalyses is proud to announce the launch of its new global commercial report "Landscape in Gene Therapy Companies". This is the first such report that provides you with an actually updated information and an accurate international mapping…..